Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Inc. (VNDA)

Market Closed
3 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
4. 97
+0.08
+1.64%
$
281.71M Market Cap
18.48 P/E Ratio
0% Div Yield
293,700 Volume
-0.01 Eps
$ 4.89
Previous Close
Day Range
4.86 5.04
Year Range
3.81 6.37
Want to track VNDA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 23 days

Summary

VNDA closed Thursday higher at $4.97, an increase of 1.64% from Wednesday's close, completing a monthly increase of 5.97% or $0.28. Over the past 12 months, VNDA stock gained 2.47%.
VNDA is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2025, missed the consensus estimates by -0.55%. On average, the company has fell short of earnings expectations by -0.16%, based on the last three reports. The next scheduled earnings report is due on Jul 29, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

VNDA Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

WASHINGTON , May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Prnewswire | 1 month ago
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.

Zacks | 1 month ago
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysantiâ„¢ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026 Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025 Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025 WASHINGTON , May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth phase with multiple commercialized products and a rich innovative pipeline.

Prnewswire | 1 month ago

Vanda Pharmaceuticals Inc. Dividends

VNDA is not paying dividends to its shareholders.

Vanda Pharmaceuticals Inc. Earnings

29 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
0.05
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
31 Jul 2024 Date
-
Cons. EPS
-
EPS
VNDA is not paying dividends to its shareholders.
29 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
0.05
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
31 Jul 2024 Date
-
Cons. EPS
-
EPS

Vanda Pharmaceuticals Inc. (VNDA) FAQ

What is the stock price today?

The current price is $4.97.

On which exchange is it traded?

Vanda Pharmaceuticals Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is VNDA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 281.71M.

When is the next earnings date?

The next earnings report will release on Jul 29, 2025.

Has Vanda Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Vanda Pharmaceuticals Inc. Profile

Biotechnology Industry
Healthcare Sector
Mihael H. Polymeropoulos CEO
NASDAQ (NMS) Exchange
921659108 Cusip
US Country
368 Employees
- Last Dividend
- Last Split
12 Apr 2006 IPO Date

Overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.

Products and Services

  • HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
    • Jet lag disorder
    • Insomnia
    • Delayed sleep phase disorder
    • Sleep disturbances in autism spectrum disorder
    • Pediatric Non-24
  • Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
    • Bipolar I disorder
    • Parkinson's disease psychosis
    • A long-acting injectable (LAI) formulation for schizophrenia
  • Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
    • Gastroparesis
    • Motion sickness
    • Atopic dermatitis
    • COVID-19 pneumonia
  • VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
    • Hematologic malignancies
    • Various oncology indications
  • VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
    • Performance anxiety
    • Psychiatric disorders
  • VHX-896 – An active metabolite of iloperidone in development.
  • Antisense Oligonucleotide Molecules – Under investigation for various indications.
  • Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
    • VSJ-110 for the treatment of dry eye and ocular inflammation
    • VPO-227 for treating secretory diarrhea disorders such as cholera

Contact Information

Address: 2200 Pennsylvania Avenue NW
Phone: 202 734 3400